CAROLINA: CV safety of linagliptin noninferior to glimepiride in patients with early T2D
04 Oct 2019
byRoshini Claire Anthony
The incidence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), or nonfatal stroke (three-point MACE*) was comparable in individuals with early stage type 2 diabetes (T2D) who received the DPP-4** inhibitor linagliptin or the sulfonylurea glimepiride in addition to usual care, according to results of the CAROLINA*** trial.